Kristina Lindemann: The prognostic value of ctDNA in patients with endometrial cancer
Kristina Lindemann, Head of the Gynecological Oncology Center at Oslo University Hospital, shared an article on LinkedIn:
“Happy to share our recent publication on the prognostic value of ctDNA in patients with endometrial cancer. Detecting ctDNA with a pan-cancer cfDNA assay in a multicenter setting is feasible and shows concordance with sequencing data on tumor samples.
We are looking forward to generating more data on its role as a dynamic disease monitoring tool in patients with endometrial cancer. Choice of panel, depth of sequencing, harmonization of processing protocols….much more to explore.
We are grateful for this collaboration supported by RAKEL OG OTTO KRISTIAN BRUUN’S LEGAT, Swiss National Science Foundation SNSF/Dr. Paul Jannsen Fellowship.”
Prognostic value of assessing ctDNA in patients with endometrial carcinoma – an international multicenter study.
Authors: Kristina Lindemann, et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023